Research programme: natural killer cell therapies - Bristol Myers Squibb/Dragonfly Therapeutics
Alternative Names: Natural killer cell engager based immunotherapies - Bristol Myers Squibb/Dragonfly TherapeuticsLatest Information Update: 28 Aug 2024
At a glance
- Originator Dragonfly Therapeutics
- Class Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis; Neurogenic inflammation
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Multiple-sclerosis in USA (Parenteral)
- 28 Aug 2024 No recent reports of development identified for research development in Neurogenic-inflammation in USA (Parenteral)
- 06 Jul 2020 Dragonfly Therapeutics and Bristol Myers Squibb agree to discover and develop immunotherapies in the US for Multiple sclerosis and Neurogenic inflammation